Proposal of a morphologic bone marrow response score for imatinib mesylate treatment in chronic myelogenous leukemia

In conclusion, morphologic criteria for complete cytogenetic response in patients with CML treated with imatinib can be defined. Persistent high-level morphologic abnormalities herald early on a high likelihood to fail treatment and call for more intense or alternative therapy.